for patients with cancer and diabetes, announced that its research collaborators were selected to present at the upcoming 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. The collaborators will present posters on positive...
11th Pharma Packaging and Labeling Innovation Forum 2024 is an executive platform to discuss the industry challenges for Material & Design Innovations, Sustainability, Branding & Marketing, and Inspirational & Active Packaging. 11th Pharma...
Epidemiology, and End Results (SEER) Program, approximately 234,580 patients will be diagnosed with lung cancer in 2024, accounting for 11.7% of all new cancer cases, with approximately 125,070 expected patient deaths from prostate cancer in 2024,...
in a timely, safe and convenient way.” This year, the CDC recommends everyone ages 6 months and older receive updated 2024-2025 COVID-19 and flu vaccines, with rare exceptions. The CDC says that the concurrent administration of both vaccines is...
CVS Health® announced that the updated 2024-2025 COVID-19 vaccines and flu vaccines are available at CVS Pharmacy® and MinuteClinic® locations nationwide. Walk-ins are being accepted at CVS Pharmacy and the company's digital vaccine scheduler has...
Phase 1 clinical study of FTX-101 in healthy volunteers. The company anticipates the commencement of the study in Q4 2024. "The FDA's clearance of our IND marks an important achievement for Find, allowing us to proceed with our Phase 1 study of...
("Corina"), developed by Yipurun (Shanghai) Biotechnology Co., Ltd. ("YPR"), has received approval in China (G.X.Z.Z. 20243181461) for use in patients with moderate-to-severe intrauterine adhesions (IUA) who undergo transcervical resection of...
Asia-Pacific League of Associations for Rheumatology Congress, set to take place in Singapore. Scheduled from 21-25 August 2024, this congress promises to be an exceptional gathering, embracing the vibrant spirit of Singapore and fostering an...
Officer of Bavarian Nordic. The order from HERA will have no impact on the Company’s overall financial guidance for 2024 but brings the total value of secured contracts close to the lower level of the revenue guidance for the Public Preparedness...
company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius...
MTX-463, with approximately three quarters of the cohorts dosed, and completion of the trial expected by the end of 2024. Additionally, MTX-463 was granted orphan drug and fast track designations by the FDA, underscoring the potential of WISP1 to...
propionate ophthalmic suspension, 0.05% (APP13007) was approved by the U.S. Food and Drug Administration (FDA) on March 4, 2024. The licensing deal will include certain payments, including an upfront payment and milestone payments upon achievement...
to minimize systemic toxicity. The trial is anticipated to conclude by mid-2025, with top-line data expected year-end 2024. Dr. Michael Chancellor, Chief Medical Officer of Lipella added, “We have heard the urgency for new effective OLP therapies...
as a fixed-dose combination. The Company began enrolling patients in BROADWAY in January 2022 and in TANDEM in March 2024; completing enrollment of BROADWAY in July 2023, and TANDEM in July 2024. The Company also commenced the Phase 3 PREVAIL...
to pursuing innovative animal drug products and technology and granted the company a sponsor fee waiver for fiscal year 2024. Innocan's LPT-CBD is a proprietary drug delivery platform designed to provide prolonged-release CBD for chronic pain and...
in patient recruitment. As a result, Teva and Sanofi now anticipate having topline results for both UC and CD in Q4 2024, and detailed results will be presented in a scientific forum in 2025. This adjustment replaces the previously planned interim...
(FDA), and the agency works with Prolacta, where and if necessary, to refine the claim language. In response to a May 2024 complaint filed by Mead Johnson & Company with the BBB National Advertising Division (NAD) challenging certain advertising...
Antibodies, and Enzymes, to a Broad Range of Cell and Tissue Types, at the mRNA Therapeutic Summit in Boston on July 29, 2024. About Mercury Bio: Sparked by scientific breakthroughs in genomic research, Mercury Bio has developed a next-generation...
further assess the clinical relevance of observed effects. Initiation of the Phase 2 is anticipated in the second half of 2024. About CK-0045: CK-0045 is a long-acting analogue of interleukin-22 (IL-22), an atypical, non-immunomodulatory cytokine...
receptor agonist, BGM0504, have been published online in Scientific Reports, a sub-journal of Nature, on July 19, 2024. Bright Gene (Stock Code: 688166.SH) is an innovative pharmaceutical company emerging on the international stage, is focused on...
